Abstract
Psychotic disorders and schizophrenia-spectrum personality disorders (PD) with psychotic/psychotic-like symptoms are considerably linked both historically and phenomenologically. In particular with regard to schizotypal and schizotypal personality disorder (SPD), this is evidenced by their placement in a joint diagnostic category of non-affective psychoses in the InternationaI Classification of Diseases 10th Revision, (CD-10) and, half-heartedly, the fifth edition of Diagnostic and Statistical Manual of Mental Disorders, (DSM-5). Historically, this close link resulted from observations of peculiarities that resembled subthreshold features of psychosis in the (premorbid) personality of schizophrenia patients and their biological relatives. These personality organizations were therefore called “borderline (schizophrenia)” in the first half of the 20th century. In the 1970s, they were renamed to “schizotypal” and separated from psychotic disorders on axis-I and from other PD on axis-II, including modern borderline PD, in the DSM. The phenomenological and historical overlap, however, has led to the common assumption that the main difference between psychotic disorders and SPD in particular was mainly one of severity or trajectory, with SPD representing a latent form of schizophrenia and/or a precursor of psychosis. Thus, psychosis proneness and schizotypy are often assessed using SPD questionnaires. In this perspective-piece, we revisit these assumptions in light of recent evidence. We conclude that schizotypy, SPD (and other schizophrenia-spectrum PD) and psychotic disorder are not merely states of different severity on one common but on qualitatively different dimensions, with the negative dimension being predictive of SPD and the positive of psychosis. Consequently, in light of the merits of early diagnosis, the differential early detection of incipient psychosis and schizophrenia-spectrum PD should be guided by the assessment of different schizotypy dimensions.
The group of psychotic disorders mainly includes non-affective (i.e., schizophrenia and schizophrenia-spectrum psychoses) and affective psychoses (i.e., mania, bipolar disorders, and depression) whose common features are positive psychotic symptoms (i.e., delusions and hallucinations) (1). Personality disorders (PD) with positive and negative psychotic-like features are assumed to be closely related to the schizophrenia spectrum; these are paranoid PD, schizoid PD, and schizotypal PD (SPD).
Despite their low lifetime prevalence of about 2% (1, 2), psychoses cause tremendous costs, burden, and disability, already in children and adolescents (3–5). Because a long duration of nontreatment of psychosis and its prodrome negatively impacts outcome (6), research on an early detection and intervention in psychosis prior to the first episode increasingly gained momentum since the 1990s. By now, clinical high-risk (CHR) criteria have already been suggested for transfer into clinical practice, e.g., within the framework of the guidance project of the European Psychiatric Association (7, 8).
The prevention of schizophrenia-spectrum PD is less clear. In the United States, the lifetime prevalence of schizophrenia-spectrum PD was 9% in adults of age ≥20; with SPD 3.9%, paranoid PD 4.3%, and schizoid PD 3.1% (9). Lower rates were reported from Norway (10) (paranoid, 2.4%; schizoid, 1.7%; SPD, 0.6%) and Germany (11) (paranoid, 1.8%; schizoid, 0.4%; SPD, 0.7%) with a higher SPD prevalence in relatives of schizophrenia patients (2.1%) (12). Little is known about the costs and burden of schizophrenia-spectrum PD beyond their assumed role of increasing risk for schizophrenia, as they are frequently not assessed in studies of societal impact of mental disorder (4, 5). Similarly, little research has specifically targeted their early detection and prevention beyond being a by-product of, e.g., research on early detection of psychosis (13).
Personality Traits and Disorders, and Psychosis
Psychoses and schizophrenia-spectrum PD, particularly SPD, are linked historically, phenomenologically, and through shared genetic and (neuro-)biological factors (14). This link is mirrored by SPD’s placement within the ICD section for schizophrenia and related disorders and its mentioning as a related disorder in the schizophrenia section of DSM-5 (15, 16). Because SPD and schizotypy—as well as other terms often used in this context such as psychotic-like experiences (17)—are not synonymous (18); in the following, we will strictly distinguish between these terms and elucidate their conceptual differences later in the manuscript (see also Table 1).
Table 1
| Schizotypy | Schizotypal disorder | Schizoid (s) and paranoid (p) PD | SPD | CHR a | Psychosis | ||
|---|---|---|---|---|---|---|---|
| General characteristic | Enduring personality trait, not per se considered as pathological character | Evolution and chronic course (alike that of a PD) with fluctuations of intensity and no definite onset (trait-state character) | An enduring pattern of inner experience and behavior (trait) that deviates markedly from the expectations of the individual’s culture, is pervasive and inflexible, has an onset in adolescence or early adulthood, is stable over time, and leads to distress or impairment | Full or at least some insight into their abnormal nature; defined onset or worsening, not part of the premorbid personality (state) | Defined onset, state (positive symptoms with no insight into their abnormal nature) | ||
| Positive factor |
|
|
|
|
|
| |
| Negative factor |
|
|
|
| Not part of CHR criteria:
|
| |
| Disorganized factor |
|
|
| Not part of CHR criteria:
|
| ||
| Cognitive factorb |
| ||||||
| Others |
|
| |||||
| Features/symptoms needed for diagnosis | Not applicable, no mental disorder | 3 or more, each present for at least 2 years | 4 or more | 5 or more | 1 or more (APS, BIPS, COPER criteria) 2 or more (COGDIS criterion) | Dependent on type of psychotic disorder | |
Current operationalizations of schizotypy, schizotypal disorder according to ICD-10, SPD and other schizophrenia-spectrum PD according to DSM-5, clinical high risk (CHR) of psychosis and psychosis (15, 19–23).
According to the Structured Interview for Psychosis-Risk Syndromes for the assessment of ultra-high risk (UHR) criteria (identified by a prefix of capital letter plus number; 23); Schizophrenia Proneness Instrument Adult/Child & Youth version for the assessment of basic symptom criteria (no prefix) (21, 22).
According to the notion of an independent (fourth) “impaired cognition”-dimension in psychosis that, however, is commonly defined by objective neurocognitive impairments (15, 19, 20).
APS, attenuated psychotic symptoms; BIPS, brief intermittent psychotic symptoms; COPER, basic symptom criterion “cognitive-perceptive basic symptoms”; COGDIS, basic symptom criterion “cognitive disturbances”.
Historical Links
Although SPD as a diagnostic entity was not formulated until 1979 (24), historically, its close link to schizophrenia-spectrum psychoses was earlier established by observations on two levels (25):
the familial level: observations of peculiarities resembling subthreshold features of psychosis in the (premorbid) personality of patients with schizophrenia and their biological relatives, and
the clinical level: observations of patients with attenuated forms of Bleuler’s fundamental symptoms of schizophrenia without positive psychotic symptoms or severe personality deterioration.
Thus, these personality organizations were commonly called “borderline or latent schizophrenia” in the first half of the 20th century; with focus on their pathological and dysfunctional aspects (including its function as a risk indicator for psychosis), the difference between manifest psychotic disorders and their latent forms (particularly SPD) has commonly been (mis-)assumed to be one of severity or trajectory.
Both Kraepelin (26) and E. Bleuler (27) had frequently observed signs of latent schizophrenia in relatives of schizophrenia patients that they regarded as “essentially the same as the principle malady” (p. 234) (26) and “qualitatively identical with those of the patients themselves so that the disease appears to be only a quantitative increase of the anomalies seen in parents and siblings” (p. 238) (27). Thus, latent schizophrenia was seen as a mild expression of illness, usually not leading to help-seeking. Their and subsequent descriptions of the abnormal personality of relatives of schizophrenia patients mostly pointed towards the following core characteristics: being eccentric-odd, irritable-unreasonable, socially withdrawn, suspicious, superstitious, nervous, and hypersensitive, exhibiting an aloof and cold demeanor, functioning poorly, and speaking oddly (25).
Emphasizing the clinical link, clinical descriptions of patients emerged since the 1940s, who—though having neither familial risk nor frank schizophrenia—exhibited substantial schizophrenia-like symptoms (25). In 1953, Rado (28) coined the term schizotype (a contraction of “schizophrenic phenotype”; engendered by a schizophrenic genotype) to describe non-psychotic but schizophrenia-like individuals (with lifelong risk for psychotic decompensation). He assumed two major abnormalities, severe anhedonia and a distorted awareness of one’s body, from which other abnormalities would result, including a propensity for cognitive disorganization and deviant, dependent social relationships.
Building up on Rado’s ideas, Meehl (29, 30) used the term schizotypy to describe trait-like manifestations of schizotaxia, an integrative neural defect caused by a dominant schizogene. Relating to Bleuler (27), the core behavioral schizotypy traits were assumed to be cognitive slippage, interpersonal aversiveness (including suspiciousness and expectation of rejection due to a negative self-image of being unlovable), ambivalence, and anhedonia, with psychosis-like features merely as accessory phenomena (18, 25). In Meehl’s model, all carriers of the schizogene are schizotaxics (i.e., a true taxon of ill individuals) and—depending on environmental influences—present with graded manifestations of schizotypy, including schizophrenia as its most severe form. Consequently, schizotaxia (as a neural defect) and schizotypy (as its manifestation) equal schizophrenia-liability, while—even under the poorest environmental circumstances—a non-schizotaxic cannot become a schizotype or a patient with schizophrenia.
While the early schizotypy approach is aimed at commonalities with schizophrenia, the DSM-III taskforce (24) targeted the differentiation between what was to become SPD and other disorders, when formulating criteria for schizophrenia-spectrum PD. Broadly in line with this first definition, SPD is still described in DSM-5 as follows:
“a pervasive pattern of social and interpersonal deficits, including reduced capacity for close relationships; cognitive or perceptual distortions; and eccentricities of behavior, usually beginning by early adulthood but in some cases first becoming apparent in childhood and adolescence” (p. 89) (15).
Thus, unsurprisingly, SPD assessments based on this disorder-oriented view, formulate items conflating schizotypy with aspects of clinical relevance and distress (31).
Current Perspective
Beginning with notions by Kretschmer (32) and Eysenck (33), the current understanding of schizotypy was heavily influenced by the European school of temperament and is subtly but decisively distinct from Meehl’s model (18). Proneness for psychosis was no longer believed to be a gradation of illness exclusive to a discrete subgroup of the general population but to be lying on a continuum graded throughout all people, with extreme expressions manifesting as disorders. Additionally, due to Schneider’s influential emphasis on positive symptoms (34), research on general temperaments included schizophrenia liability rather in terms of proneness for unusual perceptual experiences and magical/paranormal thinking than for Bleuler’s fundamental symptoms [e.g., Tellegen’s “Absorption” (35) or Cloninger’s “Self-Transcendence” (36)] (18).
Thus, building up further on Claridge’s work (37), schizotypy is currently not perceived as a single likely pathological dimension but as a multi-dimensional construct that is per se neither pathological nor equal to schizophrenia liability. Instead, at least two dimensions (positive and negative) are assumed, and it is the clustering or co-occurrence of elevated levels of them in an individual that leads to taxon-like entities like schizophrenia, SPD, or CHR (18, 38, 39). Accordingly, factor analyses of both schizotypy and SPD measures suggest that schizotypy is best understood as consisting of the same three dimensions as found in schizophrenia: a positive, a negative, and a disorganized dimension (40–42), although their conceptualization differs greatly (Table 1) (31, 43). Commonly and especially in the discussion of a continuum hypothesis of psychosis (44), most emphasis is put on the positive dimension, although Claridge’s fully dimensional model considers this dimension the one that is least (inherently) associated with schizophrenia liability.
Benign Schizotypy and “Happy” Schizotypes
Thus, in contrast to the disorder-based view of schizotypy, the temperament-based models allow for the existence of benign aspects inherent to unidimensional schizotypy that, only in excess, may become pathological. This is especially true for positive schizotypy, expressing, e.g., as spiritual experiences, feelings of interconnectedness with others and/or the environment, and personal enlightenment.
The supposition that positive schizotypy and disease proneness constitute different dimensions has been argued for (implicitly but convincingly) by Claridge and colleagues (37, 45–47) who regard the difference between mentally healthy—or even “happy” (p. 255) (46)—schizotypes and schizophrenia-spectrum patients not as one of quantity or severity of psychosis proneness but as one of quality of phenomena (Table 1) (18). These qualitative differences are due to influences of other dimensions that are linked to negative and disorganized schizotypy (18, 38, 48, 49). Being distinct from continuously distributed schizotypy, schizophrenia is, thus, regarded as a breakdown process and endpoint on a second graded continuum that starts from SPD, making it (and other disorders) taxon-like clusters of several (individually continuous) dimensions (18).
A recent review of studies on benign schizotypy (47) concluded that high positive schizotypy in itself seems more likely to be beneficial, i.e., associated with personal wellbeing, flexible and unconventional thinking (including creativity), and favorable personality traits and psychological features (e.g., openness to experience, fantasy proneness, and spirituality). In contrast to the continuum hypothesis of psychosis focusing on positive schizotypy and in line with findings on prediction of psychoses (see below), high negative schizotypy and/or high disorganized schizotypy emerged as factors relevant to psychopathological functioning and mental ill-health (47). Lately, the view on the positive dimension was detailed by a study of the effect of schizotypy on well-being (50). Next to the different negative effects of negative and disorganized SPD features on all aspects of well-being, only the positive features suspiciousness (commonly only part of SPD but not of schizotypy assessments; Table 1) and ideas of reference were significantly associated with negative affect and poor environmental mastery and with poor autonomy, respectively. Other positive features, i.e., odd beliefs/magical thinking and unusual perceptual experiences, were either significantly associated with happiness, positive affect, good environmental mastery, and good personal growth, or not related to any of these outcomes (50). Notably, physical anhedonia—which is part of the negative schizotypy dimension but not of SPD—was not assessed.
Early Detection of Psychotic Disorders
In clinical samples, the early detection of psychoses mainly follows an indicated preventive approach. Currently, a CHR state is alternatively defined by two complementary approaches (8, 51): The ultra-high risk (UHR) approach, developed to identify persons with high likelihood of transition to psychosis within the next 12 months, and the basic symptom approach, developed to detect beginning psychosis as early as possible.
The UHR criteria include the brief intermittent psychotic symptoms, the attenuated psychotic symptoms, and the “trait-state” or “genetic risk and functional decline” criterion (52, 53). The latter criterion defines the risk trait by either a first-degree family member with psychosis or by an SPD in the index patient, and the state by a functional decline. However, in clinical samples, the trait-state criterion by itself did not significantly raise risk of conversion to psychosis in recent meta-analyses (8, 54). The attenuated psychotic symptoms criterion accounts for the vast majority of CHR patients. Attenuated psychotic symptoms are mainly defined by sub-threshold psychotic-like experiences (as earlier defined on a clinical continuum by the Chapmans) (55) and by positive features of SPD (13). Nevertheless, attenuated psychotic symptoms differ from corresponding trait-like features of SPD (and paranoid PD) by their obligate recent onset or worsening (Table 1); i.e., by capturing early state-like signs of an emerging disorder that allow the initiation of an indicated prevention (13, 56). The trait-state distinction between positive schizotypy and APS was recently supported in a study showing significant changes in APS but not positive schizotypy over 1 year (57).
The basic symptom criteria include “cognitive disturbances” and the “cognitive-perceptive basic symptoms” (58, 59). Of these, the latter lacked sufficient meta-analytical evidence to be already recommended for clinical practice (7). Contrary to the trait character of schizotypy and SPD, basic symptoms decidedly have state character, as, by definition, they differ from what patients consider to be their “normal” mental self (57, 59, 60). Basic symptoms are conceptualized as the earliest primary psychopathological correlates of the neurophysiological disturbances of information processing underlying the development of attenuated and frank psychotic symptoms, which develop based on and partly in reaction to basic symptoms (61, 62). Thus, independently of any thought content or perception, basic symptoms are disturbances in mental processes themselves, thereby clearly differing from more content-related positive features of schizotypy and SPD, and attenuated and brief limited psychotic symptoms (Table 1) (60–62).
Studies of personality dimensions, schizotypy, PDs, and SPD, in CHR samples indicate the following:
CHR patients, compared to CHR-negative patients, are more often high scorers on all four higher-order personality dimensions simultaneously, i.e. emotional dysfunction, inhibitedness, dissocial behavior, and compulsivity (63), rather than exhibiting a distinct “psychosis profile,” e.g., of high neuroticism, low extraversion, and medium agreeableness and conscientiousness (64).
Studies using positive and negative schizotypy assessments, such as the four Wisconsin Schizotypy Scales (65, 66), suggest that pronounced physical anhedonia enhances risk for psychosis, though likely only in the presence of CHR states (67, 68); moreover, physical anhedonia also predicted presence of UHR but not of basic symptom criteria (67).
Studies using SPD assessments, such as the Schizotypal Personality Questionnaire (66, 69), in CHR patients indicated that SPD, particularly (paranoid) ideas of reference and lack of close friends, predicted psychosis (13) and that SPD assessment might help to identify CHR patients, especially those meeting the trait-state UHR criterion (70).
When other PD were simultaneously considered, schizoid rather than schizotypal personality traits predicted conversion to psychosis in CHR patient, mainly by deficits in social interaction (that are also partly included in schizotypy assessments of social anhedonia) but not by indifference and emotional coldness (56).
Furthermore, in clinical samples defined by schizotypal disorder, schizoid PD or SPD, up to 48% developed psychosis, which was best predicted by unusual or paranoid ideas and social isolation (13). A similar pattern of predictors was found in non-clinical genetic-risk and community samples, in which positive schizotypy and SPD assessments of unusual and paranoid ideas and unusual perceptual experiences were main predictors of psychoses, whereby social or physical anhedonia and social withdrawal further improved prediction of psychosis—but even more of schizophrenia-spectrum disorders—in some studies (13, 71). Thus, schizotypy and SDP features seem to detect psychosis early; yet, the psychosis-predictive power of single assessments seems to depend on the examined population and, likely, on the interplay between positive and negative dimensions (49). Additionally, the inherent conflation of schizotypy features with distress found in inventories based on Meehl and the SPD conceptualization must be kept in mind (31).
Furthermore, it must be observed that little is known about the role of the disorganized dimension that has hardly been studied. Thus, some effects might be misattributed to the positive and negative schizotypy dimension, as recently shown for the earlier likely misattributed association of negative affective with positive schizotypy that is better explained by one with disorganized schizotypy (72, 73).
Early Detection of Severe Schizophrenia-Spectrum Personality Disorder
Although schizotypal disorder and SPD have been studied for their propensity to predict psychosis in several studies (13), few studies have examined their predictors. An early study followed children clinically diagnosed as “schizoid” over a mean course of 18 years, whereby “schizoid” was defined by solitude, impaired empathy/emotional detachment, mental rigidity, hypersensitivity with a tendency to paranoid ideas, and odd communication (74). At follow-up, three quarters had developed SPD and 8% psychosis; only 13% had clearly recovered from their schizoid symptoms (75). Moderate stability of the three SPD dimensions across adolescence, i.e., from age 11 to age16, along with a clear indication of their heritability (h² = 38–57%) (76) at each assessment time has also been reported (77). Variance in SPD assessment scores at 16 years could be decomposed in 36% stable genetic, 3% stable environmental, 42% time-specific genetic, and 19% time-specific environmental influences, with the positive dimension score being explained by genetic variance only at age 11 years. SPD usually begins by early adulthood, and only rarely in childhood and adolescence (15). Furthermore, an increase in schizotypy and SPD severity across adolescence with a subsequent decrease in adulthood was repeatedly reported (78, 79). Thus, particularly when in concert with a parental schizophrenia-spectrum disorder, pronounced persistent or increasing schizotypy features (49) might currently be the best predictors of adult SPD in youth, especially when of the negative socially impaired and the positive paranoid-suspicious kind.
Other clinical (e.g., heightened anxiety levels), environmental (e.g., childhood adversity and trauma), genetic (e.g., Val allele of the Val158Met COMT polymorphism), neurobiological (e.g., various brain abnormalities in frontal, temporal, striatal, and parahippocampal regions), social-cognitive (e.g., poor emotion recognition), and neuropsychological (e.g., jumping-to-conclusion) risk factors of SPD resemble those described for schizophrenia (80, 81), thus not displaying a unique pattern that could be used for its prediction specifically.
Conclusions
We conclude that schizotypy, SPD (and likely other schizophrenia-spectrum PD), and psychotic disorder are rather manifestations of discrete profiles (i.e., qualitatively distinct taxon-like clusters) of schizotypy or SPD dimensions than merely states of different severity on only one dimension. In doing so, positive schizotypy features—other than the distressing SPD feature of paranoid ideas of reference and suspiciousness—do not appear to be pathognomonic by themselves. This is in contrast to continuum models of psychosis that mainly rely on positive features and assume a progression from positive schizotypy and SPD traits via psychotic-like experiences and attenuated psychotic symptoms to psychotic positive symptoms and, finally, schizophrenia (44). Pathological personality processes rather seem to require an interaction of the positive dimension with the negative and/or disorganized dimension, at which, of the positive features, trait-like distressing paranoid ideas of reference and suspiciousness, which are unique to the positive SPD dimension, seem to be most relevant and a starting point on the suggested SPD-psychosis continuum that is distinct from the potentially benign positive schizotypy dimension. The SPD-psychosis continuum, however, likely also involves state-like subclinical positive symptoms such as UHR symptoms that are predictive of psychosis. In doing so, the trait or state character of the positive features might be crucial for the development of SPD or psychosis in late adolescence or young adulthood.
In light of the merits of early diagnosis, a differential early detection of incipient psychotic disorders and schizophrenia-spectrum PD, guided by a comprehensive assessment of all relevant schizotypy-SPD-psychosis dimensions, is necessary—also in light of calls for dimensional diagnostic systems (82), yet requires more research into their differential prediction.
Statements
Author contributions
FS-L was responsible for the conception of the work and drafted the first versions of this work. PG and IN revised it critically for important intellectual contents. All authors provided approval for publication of the content.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
ChangWCWongCSChenEYLamLCChanWCNgRMet al. Lifetime prevalence and correlates of schizophrenia-spectrum, affective, and other non-affective psychotic disorders in the Chinese adult population. Schizophr Bull (2017) 43(6):1280–90. doi: 10.1093/schbul/sbx056
2
Moreno-KüstnerBMartínCPastorL. Prevalence of psychotic disorders and its association with methodological issues. PLoS One (2018) 13(4):e0195687. doi: 10.1371/journal.pone.0195687
3
GoreFMBloemPJPattonGCFergusonJJosephVCoffeyCet al. Global burden of disease in young people aged 10–24 years: a systematic analysis. Lancet (2011) 377(9783):2093–102. doi: 10.1016/S0140-6736(11)60512-6
4
GustavssonASvenssonMJacobiFAllgulanderCAlonsoJBeghiEet al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol (2011) 21(10):718–79. doi: 10.1016/j.euroneuro.2011.08.008
5
WittchenHUJacobiFRehmJGustavssonASvenssonMJönssonBet al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol (2011) 21(9):655–79. doi: 10.1016/j.euroneuro.2011.07.018
6
Dell’ossoBAltamuraAC. Duration of untreated psychosis and duration of untreated illness: new vistas. CNS Spectr (2010) 15(4):238–46. doi: 10.1017/S1092852900000079
7
Schultze-LutterFMichelCSchmidtSJSchimmelmannBGMaricNPSalokangasRKet al. EPA guidance on the early detection of clinical high risk states of psychoses. Eur Psychiatry (2015) 30(3):405–16. doi: 10.1016/j.eurpsy.2015.01.010
8
SchmidtSJSchultze-LutterFSchimmelmannBGMaricNPSalokangasRKRiecher-RösslerAet al. EPA guidance on the early intervention in clinical high risk states of psychoses. Eur Psychiatry (2015) 30(3):388–404. doi: 10.1016/j.eurpsy.2015.01.013
9
QuirkSEEl-GabalawyRBrennanSLBoltonJMSareenJBerkMet al. Personality disorders and physical comorbidities in adults from the United States: data from the national epidemiologic survey on alcohol and related conditions. Soc Psychiatry Psychiatr Epidem (2015) 50(5):807–20. doi: 10.1007/s00127-014-0974-1
10
TorgersenSKringlenECramerV. The prevalence of personality disorders in a community sample. Arch Gen Psychiatry (2001) 58(6):590–6. doi: 10.1001/archpsyc.58.6.590
11
MaierWLichtermannDKlinglerTHeunRHallmayerJ. Prevalences of personality disorders (DSM-III-R) in the community. J Pers Disord (1992) 6(3):187–96. doi: 10.1521/pedi.1992.6.3.187
12
MaierWLichtermannDMingesJHeunR. Personality disorders among the relatives of schizophrenia patients. Schizophr Bull (1994) 20(3):481–93. doi: 10.1093/schbul/20.3.481
13
DebbanéMEliezSBadoudDConusPFlückigerRSchultze-LutterF. Developing psychosis and its risk states through the lens of schizotypy. Schizophr Bull (2015) 41(Suppl 2):S396–407. doi: 10.1093/schbul/sbu176
14
VollemaMGSitskoornMMAppelsMCKahnRS. Does the schizotypal personality questionnaire reflect the biological-genetic vulnerability to schizophrenia? Schizophr Res (2002) 54(1–2):39–45. doi: 10.1016/S0920-9964(01)00350-4
15
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5.Arlington, VA: American Psychiatric Association (2013). 943 p. doi: 10.1176/appi.books.9780890425596
16
World Health Organization. International statistical classification of diseases and related health problems.Geneva: WHO (1994). 750 p.
17
Schultze-LutterFSchimmelmannBGRuhrmannS. The near Babylonian speech confusion in early detection of psychosis. Schizophr Bull (2011) 37(4):653–5. doi: 10.1093/schbul/sbr039
18
GrantPGreenMJMasonO. Models of schizotypy: the importance of conceptual clarity. Schizophr Bull (2018) 44(S2): S556–63. doi: 10.1093/schbul/sby012
19
HeckersSBarchDMBustilloJGaebelWGurRMalaspinaDet al. Structure of the psychotic disorders classification in DSM-5. Schizophr Res (2013) 150(1):11–4. doi: 10.1016/j.schres.2013.04.039
20
BarchDMBustilloJGaebelWGurRHeckersSMalaspinaDet al. Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: relevance to DSM-5. Schizophr Res (2013) 150(1):15–20. doi: 10.1016/j.schres.2013.04.027
21
Schultze-LutterFKochE. Schizophrenia Proneness Instrument: Child and Youth version (SPI-CY). Rom: Fioriti (2010). 98 p.
22
Schulze-LutterFAddingtonJ. Schizophrenia Proneness Instrument, Adult version (SPI-A). Roma: Giovanni Fioriti Editore (2007). 91 p.
23
McGlashanTHWalshBWoodsS. The psychosis-risk syndrome: handbook for diagnosis and follow-up. New York: Oxford University Press (2010). 243 p.
24
SpitzerRLEndicottJGibbonM. Crossing the border into borderline personality and borderline schizophrenia. Arch Gen Psychiatry (1979) 36(1):17–24. doi: 10.1001/archpsyc.1979.01780010023001
25
KendlerKS. Diagnostic approaches to schizotypal personality disorder: a historical perspective. Schizophr Bull (1985) 11(4):538–53. doi: 10.1093/schbul/11.4.538
26
KraepelinE. Dementia praecox and paraphrenia. Miami, FL: HardPress Pub (2013). 331 p.
27
BleulerE. Dementia praecox: oder gruppe der schizophrenien. Leipzig, Wien: Deuticke (1911). 416 p.
28
RadoS. Dynamics and classification of disordered behavior. Am J Psychiatry (1953) 110(6):406–16. doi: 10.1176/ajp.110.6.406
29
MeehlPE. Schizotaxia, schizotypy, schizophrenia. Am Psychol (1962) 17:827–38. doi: 10.1037/h0041029
30
MeehlP. Toward an integrated theory of schizotaxia, schizotypy, and schizophrenia. J Pers Dis (1990) 4:1–99. doi: 10.1521/pedi.1990.4.1.1
31
OezgenMGrantP. Odd and disorganized—comparing the factor structure of the three major schizotypy inventories. Psychiatry Res (2018) 267:289–95. doi: 10.1016/j.psychres.2018.06.009
32
KretschmerE. Körperbau und charakter: untersuchungen zum konstitutionsproblem und zur lehre von den tempramenten. Berlin: Springer (1921). 192 p.
33
EysenckHJ. The scientific study of personality. London: Routledge & Kegan Paul (1952). 320 p.
34
SchneiderK. Klinische psychopathologie. Stuttgart, New York: Thieme (1992). 117 p.
35
TellegenA. Brief manual for the multidimensional personality questionnaire: unpublished manuscript. Minneapolis: University of Minnesota (1982).
36
CloningerCRSvrakicDMPrzybeckTR. A psychobiological model of temperament and character. Arch Gen Psychiatry (1993) 50(12):975–90. doi: 10.1001/archpsyc.1993.01820240059008
37
ClaridgeG. Theoretical background and issues. In: ClaridgeG, editor. Schizotypy: implications for illness and health. Oxford New York: Oxford University Press (1997) 345:3–18. doi: 10.1093/med:psych/9780198523536.001.0001
38
Barrantes-VidalNGrantPKwapilTR. The role of schizotypy in the study of the etiology of schizophrenia spectrum disorders. Schizophr Bull (2015) 41(Suppl 2):S408–16. doi: 10.1093/schbul/sbu191
39
MasonOJ. The duality of schizotypy: is it both dimensional and categorical? Front Psychiatry (2014) 5:134. doi: 10.3389/fpsyt.2014.00134
40
LiddlePF. The symptoms of chronic schizophrenia. Br J Psychiatry (1987) 151:145–51. doi: 10.1192/bjp.151.2.145
41
VollemaMGvan den BoschRJ. The multidimensionality of schizotypy. Schizophr Bull (1995) 21(1):19–31. doi: 10.1093/schbul/21.1.19
42
NelsonMTSealMLPantelisCPhillipsLJ. Evidence of a dimensional relationship between schizotypy and schizophrenia: a systematic review. Neurosci Biobehav Rev (2013) 37(3):317–27. doi: 10.1016/j.neubiorev.2013.01.004
43
GrossGMMellinJSilviaPJBarrantes-VidalNKwapilTR. Comparing the factor structure of the wisconsin schizotypy scales and the schizotypal personality questionnaire. Personal Disord (2014) 5(4):397–405. doi: 10.1037/per0000090
44
Fonseca PedreroEDebbanéM. Schizotypal traits and psychotic-like experiences during adolescence: an update. Psicothema (2017) 29(1):5–17. doi: 10.7334/psicothema2016.209
45
JacksonM. Beningn schizotypy? The case of spiritual experience. In: ClaridgeG, editor. Schizotypy: implications for illness and health.Oxford New York: Oxford University Press (1997).
46
McCreeryC. Hallucinations and arousability: pointers to a theory of psychosis. In: ClaridgeG, editor. Schizotypy: implications for illness and health.Oxford New York: Oxford University Press (1997). doi: 10.1093/med:psych/9780198523536.003.0012
47
MohrCClaridgeG. Schizotypy—do not worry, it is not all worrisome. Schizophr Bull (2015) 41(Suppl 2):S436–43. doi: 10.1093/schbul/sbu185
48
GrantP. Genetic associations: the basis of schizotypy. In: ClaridgeGMasonO, editors. Schizotypy: new dimensions.London: Routledge (2015). p. 48–61. doi: 10.4324/9781315858562-4
49
GrantP. Is schizotypy per se a suitable endophenotype of schizophrenia?—Do not forget to distinguish positive from negative facets. Front Psychiatry (2015) 6. doi: 10.3389/fpsyt.2015.00143
50
FumeroAMarreroRJFonseca-PedreroE. Well-being in schizotypy: the effect of subclinical psychotic experiences. Psicothema (2018) 30(2):177–82. doi: 10.7334/psicothema2017.100
51
Fusar-PoliPBorgwardtSBechdolfAAddingtonJRiecher-RösslerASchultze-LutterFet al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry (2013) 70(1):107–20. doi: 10.1001/jamapsychiatry.2013.269
52
YungARPhillipsLJMcGorryPDMcFarlaneCAFranceySHarriganSet al. Prediction of psychosis. Br J Psychiatry Suppl (1998) 172(33):14–20. doi: 10.1192/S0007125000297602
53
PhillipsLJYungARMcGorryPD. Identification of young people at risk of psychosis: validation of personal assessment and crisis evaluation clinic intake criteria. Aust N Z J Psychiatry (2000) 34(Suppl):S164–9. doi: 10.1080/000486700239
54
Fusar-PoliPCappucciatiMBorgwardtSWoodsSWAddingtonJNelsonBet al. Heterogeneity of psychosis risk within individuals at clinical high risk: a meta-analytical stratification. JAMA Psychiatry (2016) 73(2):113–20. doi: 10.1001/jamapsychiatry.2015.2324
55
ChapmanLJChapmanJP. Scales for rating psychotic and psychotic-like experiences as continua. Schizophr Bull (1980) 6(3):477–89. doi: 10.1093/schbul/6.3.476
56
Schultze-LutterFKlosterkötterJMichelCWinklerKRuhrmannS. Personality disorders and accentuations in at-risk persons with and without conversion to first-episode psychosis. Early Interv Psychiatry (2012) 6(4):389–98. doi: 10.1111/j.1751-7893.2011.00324.x
57
MichelCFlückigerRKindlerJHublDKaessMSchultze-LutterF. The trait-state distinction of schizotypy and clinical high risk: results from a 1-year follow-up. World Psychiatry (2019) 18(1). doi: 10.1002/wps.20595
58
Schultze-LutterFKlosterkötterJPickerHSteinmeyerE-MRuhrmannS. Predicting first-episode psychosis by basic symptom criteria. Clin Neuropsychiatry (2007) 4(1):11–22.
59
Schultze-LutterFRuhrmannSFusar-PoliPBechdolfASchimmelmannBGKlosterkötterJ. Basic symptoms and the prediction of first-episode psychosis. Curr Pharm Des (2012) 18(4):351–7. doi: 10.2174/138161212799316064
60
Schultze-LutterFTheodoridouA. The concept of basic symptoms: its scientific and clinical relevance. World Psychiatry (2017) 16(1):104–5. doi: 10.1002/wps.20404
61
Schultze-LutterFDebbanéMTheodoridouAWoodSJRaballoAMichelCet al. Revisiting the basic symptom concept: toward translating risk symptoms for psychosis into neurobiological targets. Front Psychiatry (2016) 7:9. doi: 10.3389/fpsyt.2016.00009
62
Schultze-LutterFRuhrmannSMichelCKindlerJSchimmelmannBGSchmidtSJ. Age effects on basic symptoms in the community: a route to gain new insight into the neurodevelopment of psychosis? Eur Arch Psychiatry Clin Neurosci (2018). doi: 10.1007/s00406-018-0949-4
63
Schultze-LutterFKlosterkötterJNikolaidesARuhrmannS. Personality dimensions in persons symptomatically at risk of psychosis: pronounced but lacking a characteristic profile. Early Interv Psychiatry (2015) 9(3):242–7. doi: 10.1111/eip.12147
64
DinzeoTJDochertyNM. Normal personality characteristics in schizophrenia: a review of the literature involving the FFM. J Nerv Ment Dis (2007) 195(5):421–9. doi: 10.1097/01.nmd.0000253795.69089.ec
65
KwapilTRBarrantes-VidalNSilviaPJ. The dimensional structure of the Wisconsin schizotypy scales: factor identification and construct validity. Schizophr Bull (2008) 34(3):444–57. doi: 10.1093/schbul/sbm098
66
MasonOJ. The assessment of schizotypy and its clinical relevance. Schizophr Bull (2015) 41(Suppl 2):S374–85. doi: 10.1093/schbul/sbu194
67
FlückigerRRuhrmannSDebbanéMMichelCHublDSchimmelmannBGet al. Psychosis-predictive value of self-reported schizotypy in a clinical high-risk sample. J Abnorm Psychol (2016) 125(7):923–32. doi: 10.1037/abn0000192
68
BangMParkJYKimKRLeeSYSongYYKangJIet al. Psychotic conversion of individuals at ultra-high risk for psychosis: the potential roles of schizotypy and basic symptoms. Early Interv Psychiatry (2017). doi: 10.1111/eip.12518
69
RaineA. The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophr Bull (1991) 17(4):555–64. doi: 10.1093/schbul/17.4.555
70
ZhangTLiHTangYLiHZhengLGuoQet al. Screening schizotypal personality disorder for detection of clinical high risk of psychosis in Chinese mental health services. Psychiatry Res (2015) 228(3):664–70. doi: 10.1016/j.psychres.2015.04.049
71
KendlerKSWalshD. Schizotypal personality disorder in parents and the risk for schizophrenia in siblings. Schizophr Bull (1995) 21(1):47–52. doi: 10.1093/schbul/21.1.47
72
GrantPHennigJ. Stress induced cortisol release and schizotypy—the importance of cognitive slippage and neuroticism. Psychoneuroendocrinology (2018) 96:142. doi: 10.1016/j.psyneuen.2018.06.016
73
KempKCGrossGMBarrantes-VidalNKwapilTR. Association of positive, negative, and disorganized schizotypy dimensions with affective symptoms and experiences. Psychiatry Res (2018) 270:1145–9. doi: 10.1016/j.psychres.2018.10.031
74
WolffS. ‘Schizoid’ personality in childhood and adult life. Br J Psychiatry (1991) 159:615–20, 634–5. doi: 10.1192/bjp.159.5.615
75
WolffSTownshendRMcGuireRJWeeksDJ. ‘Schizoid’ personality in childhood and adult life. Br J Psychiatry (1991) 159:620–9, 634–5. doi: 10.1192/bjp.159.5.620
76
LinneyYMMurrayRMPetersERMacDonaldAMRijsdijkFShamPC. A quantitative genetic analysis of schizotypal personality traits. Psychol Med (2003) 33(5):803–16. doi: 10.1017/S0033291703007906
77
EricsonMTuvbladCRaineAYoung-WolffKBakerLA. Heritability and longitudinal stability of schizotypal traits during adolescence. Behav Genet (2011) 41(4):499–511. doi: 10.1007/s10519-010-9401-x
78
BoraEBaysan ArabaciL. Effect of age and gender on schizotypal personality traits in the normal population. Psychiatry Clin Neurosci (2009) 63(5):663–9. doi: 10.1111/j.1440-1819.2009.02011.x
79
Fonseca-PedreroELemos-GiráldezSMuñizJGarcía-CuetoECampillo-AlvarezA. Schizotypy in adolescence: the role of gender and age. J Nerv Ment Dis (2008) 196(2):161–5. doi: 10.1097/NMD.0b013e318162aa79
80
RosellDRFuttermanSEMcMasterASieverLJ. Schizotypal personality disorder: a current review. Curr Psychiatry Rep (2014) 16(7):452. doi: 10.1007/s11920-014-0452-1
81
WongKKRaineA. Developmental aspects of schizotypy and suspiciousness: a review. Curr Behav Neurosci Rep (2018) 5(1):94–101. doi: 10.1007/s40473-018-0144-y
82
MoreyLCBensonKTBuschAJSkodolAE. Personality disorders in DSM-5: emerging research on the alternative model. Curr Psychiatry Rep (2015) 17(4):558. doi: 10.1007/s11920-015-0558-0
Summary
Keywords
psychosis, schizotypy, schizotypal personality disorder, prediction, positive dimension, negative dimension, disorganized dimension
Citation
Schultze-Lutter F, Nenadic I and Grant P (2019) Psychosis and Schizophrenia-Spectrum Personality Disorders Require Early Detection on Different Symptom Dimensions. Front. Psychiatry 10:476. doi: 10.3389/fpsyt.2019.00476
Received
29 November 2018
Accepted
17 June 2019
Published
11 July 2019
Volume
10 - 2019
Edited by
Paola Rocca, University of Turin, Italy
Reviewed by
Armando D’Agostino, University of Milan, Italy; Nadja Heym, Nottingham Trent University, United Kingdom
Updates
Copyright
© 2019 Schultze-Lutter, Nenadic and Grant.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frauke Schultze-Lutter, frauke.schultze-lutter@lvr.de
This article was submitted to Psychopathology, a section of the journal Frontiers in Psychiatry
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.